Q&A with Chris Meissner, Meissner Filtration Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Chris Meissner, Meissner Filtration Products
A Q&A with Chris Meissner, president of Meissner Filtration Products, on recent industry trends.

Pharmaceutical Technology
Volume 36, Issue 3, pp. 88

PharmTech:



Do you see a new industry trend emerging?

Meissner:

There are many new industry trends, but very few have broad appeal that haven't already been discussed at some length. One trend that continues to be worth watching closely is how the industry continues to evolve as it faces a shrinking pipeline of promising new drugs, while also facing escalating R&D costs and increasing regulatory scrutiny. In recent years, the trend has been to partner with emerging biotechnology companies. As profitable drugs move off patent, companies are taking a second look at competing with generic competition by tackling that competition head on. They're investing in more efficient processes and, in some cases, even acquiring generic drug manufacturing companies. Key suppliers will also be expected to evolve and will be relied on to bring core competencies to bear more economically than in-house-derived solutions.

PharmTech:

How will the industry remain innovative as it reduces spending on research?

Meissner:

Spending less money on research actually increases the need for innovation rather than dampening it. The desire to fund only those projects that have the best chance of commercial success has always been high, but differentiating which of those projects are most likely to succeed remains a very difficult task. Additionally, the path to success with almost every project will likely be challenged at various times by obstacles that are best overcome with innovation.

Smaller, dynamic biotechnology firms have always relied on key suppliers to assist them with innovative solutions to overcome obstacles such as process bottlenecks. Now pharmaceutical companies of every size, many of whom have historically been vertically integrated from R&D through manufacturing, are increasingly relying on partners to conceive cost-effective solutions, effectively outsourcing many challenges. Our customers increasingly rely on us to enhance their R&D and manufacturing efficiency thereby stretching budgets as far as possible.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
25%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here